Speakers

Kalpana Vanam, MBA began her role at Lupin in 2019, holding role increasing responsibility in Regulatory Affairs functions. In her current role she is responsible for managing all US Generics, Biosimilars and Specialty portfolio. Kalpana leads regulatory strategy for all Lupin extensive product portfolio encompasses diverse and complex pharmaceutical formulations, including oral solids, injectables, inhalation products, biosimilars and Specialty products including APIs from development to launch and life cycle management. Spanning more than 35+ years of career, Kalpana started her professional journey as a Regulatory/Global Regulatory in the generic/specialty pharmaceutical industry, integrating regulatory strategy into drug development across multiple dosage forms. Before joining Lupin, he held many regulatory affairs positions at Sandoz, Taro, Pfizer, Thames, Sun and Glenmark. Kalpana has an MBA in Healthcare Management and a Master’s in Microbiology.